Hepatect Cp (Human Hepatitis B Immunoglobulin)

Hepatect Cp is indicated for the prevention of hepatitis B virus infection in several clinical situations.

• Post‑exposure prophylaxis for individuals with known or suspected exposure to hepatitis B virus.
• Prevention of hepatitis B transmission to newborns of mothers who are hepatitis B surface antigen positive.
• Supplementation of hepatitis B vaccine in persons with inadequate immune response.
• Use in patients undergoing liver transplantation who are at risk for hepatitis B reactivation.
• Administration to healthcare workers after occupational needlestick injuries involving hepatitis B‑positive sources.

The safety profile of Hepatect Cp reflects the typical reactions observed with human immunoglobulin products administered intravenously.

Common

• Mild fever or chills during or shortly after infusion.
• Headache or dizziness.
• Nausea, vomiting, or abdominal discomfort.
• Localized pain or erythema at the infusion site.

Serious

• Acute allergic reactions such as urticaria, bronchospasm, or anaphylaxis.
• Hemolysis or renal impairment associated with high‑dose immunoglobulin.
• Thromboembolic events, including deep‑vein thrombosis or pulmonary embolism.

Before initiating Hepatect Cp, clinicians should evaluate patient history and monitor for conditions that may increase the risk of adverse events.

• Assess for known hypersensitivity to human immunoglobulin or any product component.
• Evaluate renal function, especially in patients with pre‑existing kidney disease.
• Use caution in individuals with a history of thromboembolic disorders.
• Monitor for signs of hemolysis in patients with blood‑group incompatibilities.
• Avoid rapid infusion rates; adjust infusion speed based on tolerance.
• Consider pregnancy and lactation status, as safety data are limited.

Hepatect Cp may interact with other medications or clinical conditions that affect immune response or blood viscosity.

Avoid

• Concurrent administration of other immunoglobulin products without appropriate spacing.
• Use with live vaccines during the same infusion period.

Use with caution

• Anticoagulants or antiplatelet agents, due to potential increased risk of bleeding.
• Diuretics, as they may influence renal handling of immunoglobulin.
• High‑dose steroids, which can modify immune response and mask infusion reactions.
• Cytotoxic chemotherapy, requiring close monitoring for additive immunosuppression.